Cargando…
Protective Effects of Higher Exposure to Aspirin and/or Clopidogrel on the Occurrence of Hip Fracture among Diabetic Patients: A Retrospective Cohort Study
Aspirin and clopidogrel are commonly prescribed alone or together among the type 2 diabetes mellitus (T2DM) patients, and both agents could affect bone metabolism. This study aimed at demonstrating the effects of the dosage and the duration of aspirin and/or clopidogrel alone or together on the occu...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599449/ https://www.ncbi.nlm.nih.gov/pubmed/36289888 http://dx.doi.org/10.3390/biomedicines10102626 |
_version_ | 1784816596748861440 |
---|---|
author | Mao, Jui-Ting Lai, Jung-Nien Fu, Yi-Hsiu Yip, Hei-Tung Lai, Yen-Chun Hsu, Chung-Y. Chen, Sung-Hsiung Kuo, Shu-Jui |
author_facet | Mao, Jui-Ting Lai, Jung-Nien Fu, Yi-Hsiu Yip, Hei-Tung Lai, Yen-Chun Hsu, Chung-Y. Chen, Sung-Hsiung Kuo, Shu-Jui |
author_sort | Mao, Jui-Ting |
collection | PubMed |
description | Aspirin and clopidogrel are commonly prescribed alone or together among the type 2 diabetes mellitus (T2DM) patients, and both agents could affect bone metabolism. This study aimed at demonstrating the effects of the dosage and the duration of aspirin and/or clopidogrel alone or together on the occurrence of hip fracture among T2DM patients. We chose the patients newly diagnosed with T2DM and divided them into four subgroups which are under aspirin monotherapy (78,522 patients), clopidogrel monotherapy (12,752 patients), dual therapy (7209 patients), and patients not taking antiplatelet drugs (401,686 patients). We found that only higher dosage (>360 cumulative daily defined dose (cDDD)) and longer duration (≥3 years) of antiplatelet agents could be associated with lower fracture risk. Compared with the subjects taking <1-year dual agents, the risk of hip fracture was 0.38-fold for the patients taking ≥3-year dual agents. Lower dosage (28–179 cDDD) and shorter duration (1~2 years) could even be associated with higher fracture risk. Overall, the best regimen to fend off the hip fracture was the use of aspirin and clopidogrel for ≥3 years. |
format | Online Article Text |
id | pubmed-9599449 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95994492022-10-27 Protective Effects of Higher Exposure to Aspirin and/or Clopidogrel on the Occurrence of Hip Fracture among Diabetic Patients: A Retrospective Cohort Study Mao, Jui-Ting Lai, Jung-Nien Fu, Yi-Hsiu Yip, Hei-Tung Lai, Yen-Chun Hsu, Chung-Y. Chen, Sung-Hsiung Kuo, Shu-Jui Biomedicines Article Aspirin and clopidogrel are commonly prescribed alone or together among the type 2 diabetes mellitus (T2DM) patients, and both agents could affect bone metabolism. This study aimed at demonstrating the effects of the dosage and the duration of aspirin and/or clopidogrel alone or together on the occurrence of hip fracture among T2DM patients. We chose the patients newly diagnosed with T2DM and divided them into four subgroups which are under aspirin monotherapy (78,522 patients), clopidogrel monotherapy (12,752 patients), dual therapy (7209 patients), and patients not taking antiplatelet drugs (401,686 patients). We found that only higher dosage (>360 cumulative daily defined dose (cDDD)) and longer duration (≥3 years) of antiplatelet agents could be associated with lower fracture risk. Compared with the subjects taking <1-year dual agents, the risk of hip fracture was 0.38-fold for the patients taking ≥3-year dual agents. Lower dosage (28–179 cDDD) and shorter duration (1~2 years) could even be associated with higher fracture risk. Overall, the best regimen to fend off the hip fracture was the use of aspirin and clopidogrel for ≥3 years. MDPI 2022-10-19 /pmc/articles/PMC9599449/ /pubmed/36289888 http://dx.doi.org/10.3390/biomedicines10102626 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mao, Jui-Ting Lai, Jung-Nien Fu, Yi-Hsiu Yip, Hei-Tung Lai, Yen-Chun Hsu, Chung-Y. Chen, Sung-Hsiung Kuo, Shu-Jui Protective Effects of Higher Exposure to Aspirin and/or Clopidogrel on the Occurrence of Hip Fracture among Diabetic Patients: A Retrospective Cohort Study |
title | Protective Effects of Higher Exposure to Aspirin and/or Clopidogrel on the Occurrence of Hip Fracture among Diabetic Patients: A Retrospective Cohort Study |
title_full | Protective Effects of Higher Exposure to Aspirin and/or Clopidogrel on the Occurrence of Hip Fracture among Diabetic Patients: A Retrospective Cohort Study |
title_fullStr | Protective Effects of Higher Exposure to Aspirin and/or Clopidogrel on the Occurrence of Hip Fracture among Diabetic Patients: A Retrospective Cohort Study |
title_full_unstemmed | Protective Effects of Higher Exposure to Aspirin and/or Clopidogrel on the Occurrence of Hip Fracture among Diabetic Patients: A Retrospective Cohort Study |
title_short | Protective Effects of Higher Exposure to Aspirin and/or Clopidogrel on the Occurrence of Hip Fracture among Diabetic Patients: A Retrospective Cohort Study |
title_sort | protective effects of higher exposure to aspirin and/or clopidogrel on the occurrence of hip fracture among diabetic patients: a retrospective cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599449/ https://www.ncbi.nlm.nih.gov/pubmed/36289888 http://dx.doi.org/10.3390/biomedicines10102626 |
work_keys_str_mv | AT maojuiting protectiveeffectsofhigherexposuretoaspirinandorclopidogrelontheoccurrenceofhipfractureamongdiabeticpatientsaretrospectivecohortstudy AT laijungnien protectiveeffectsofhigherexposuretoaspirinandorclopidogrelontheoccurrenceofhipfractureamongdiabeticpatientsaretrospectivecohortstudy AT fuyihsiu protectiveeffectsofhigherexposuretoaspirinandorclopidogrelontheoccurrenceofhipfractureamongdiabeticpatientsaretrospectivecohortstudy AT yipheitung protectiveeffectsofhigherexposuretoaspirinandorclopidogrelontheoccurrenceofhipfractureamongdiabeticpatientsaretrospectivecohortstudy AT laiyenchun protectiveeffectsofhigherexposuretoaspirinandorclopidogrelontheoccurrenceofhipfractureamongdiabeticpatientsaretrospectivecohortstudy AT hsuchungy protectiveeffectsofhigherexposuretoaspirinandorclopidogrelontheoccurrenceofhipfractureamongdiabeticpatientsaretrospectivecohortstudy AT chensunghsiung protectiveeffectsofhigherexposuretoaspirinandorclopidogrelontheoccurrenceofhipfractureamongdiabeticpatientsaretrospectivecohortstudy AT kuoshujui protectiveeffectsofhigherexposuretoaspirinandorclopidogrelontheoccurrenceofhipfractureamongdiabeticpatientsaretrospectivecohortstudy |